



Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis

KE Duhig,^a PT Seed,^a JE Myers,^b R Bahl,^c G Bambridge,^d S Barnfield,^e J Ficquet,^f JC Girling,^g A Khalil,^{h,i} AH Shennan,^a LC Chappell,^a RM Hunter^j

^a Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, UK ^b The Division of Developmental Biology and Medicine, University of Manchester, Manchester, UK ^c University Hospitals Bristol NHS Foundation Trust, Bristol, UK ^d Kingston Hospital NHS Foundation Trust, Kingston upon Thames, UK ^e North Bristol NHS Trust, Bristol, UK ^f Royal United Hospitals Bath, Bath, UK ^g West Middlesex University Hospital, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK ^h Fetal Medicine Unit, St George's Hospital, St George's University of London, London, UK ⁱ Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK ^j Research Department of Primary Care and Population Health, University College London, London, UK

Correspondence: Dr KE Duhig, Department of Women and Children's Health, School of Life Course Sciences, King's College London, Westminster Bridge Road, London SE1 7EH, UK. Email: kate.duhig@kcl.ac.uk

Accepted 10 June 2019. Published Online 17 July 2019.

Objective To calculate the cost-effectiveness of implementing PIGF testing alongside a clinical management algorithm in maternity services in the UK, compared with current standard care.

Design Cost-effectiveness analysis.

Setting Eleven maternity units participating in the PARROT stepped-wedge cluster-randomised controlled trial.

Population Women presenting with suspected pre-eclampsia between 20⁺⁰ and 36⁺⁶ weeks' gestation.

Methods Monte Carlo simulation utilising resource use data and maternal adverse outcomes.

Main outcome measures Cost per maternal adverse outcome prevented.

Results Clinical care with PIGF testing costs less than current standard practice and resulted in fewer maternal adverse outcomes. There is a total cost-saving of UK£149 per patient tested, when

including the cost of the test. This represents a potential cost-saving of UK£2,891,196 each year across the NHS in England.

Conclusions Clinical care with PIGF testing is associated with the potential for cost-savings per participant tested when compared with current practice via a reduction in outpatient attendances, and improves maternal outcomes. This economic analysis supports a role for implementation of PIGF testing in antenatal services for the assessment of women with suspected pre-eclampsia.

Keywords Economic analysis, placental growth factor, pre-eclampsia.

Tweetable abstract Placental growth factor testing for suspected pre-eclampsia is cost-saving and improves maternal outcomes.

Linked article This article is commented on by AB Caughey, p. 1399 in this issue. To view this mini commentary visit <https://doi.org/10.1111/1471-0528.15889>.

Please cite this paper as: Duhig KE, Seed PT, Myers JE, Bahl R, Bambridge G, Barnfield S, Ficquet J, Girling JC, Khalil A, Shennan AH, Chappell LC, Hunter RM. Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis. *BJOG* 2019;126:1390–1398.

Introduction

Hypertension in pregnancy affects up to 10% of pregnant women. Pre-eclampsia complicates 2.8% of singleton pregnancies¹ and is associated with maternal and perinatal adverse outcomes.² In 2012, the cost of pre-eclampsia within the first 12 months of delivery was US\$2.18 billion in the USA.³

Around 10% of pregnant women will be investigated for suspected pre-eclampsia, making it among the most

common clinical presentations to obstetric emergency services. The diagnosis of pre-eclampsia is clinically challenging. Commonly used methods of investigation such as blood pressure measurement and proteinuria assessment demonstrate highly variable test performance.^{4–6} Ultrasound scanning and maternal admission are costly. Iatrogenic preterm birth associated with the disease is resource-intensive.^{7–9} In prospective observational cohort studies, placental growth factor (PIGF) <5th centile has good test performance in assessing women with suspected

pre-eclampsia for determining need for delivery for pre-eclampsia within 14 days of testing.¹⁰ We recently reported in the Placental growth factor for the Assessment of hypertensive pregnant women: a stepped wedge Trial (PARROT) that PIGF testing used alongside a clinical management algorithm reduced the time to diagnosis of pre-eclampsia from 4.1 days (usual care) to 1.9 days (intervention).¹¹ Where PIGF was implemented, severe maternal adverse outcomes¹² were reduced from 5.4% (24/447; usual care group) to 3.8% (22/573; intervention group), with no evidence of a difference in gestation at delivery (36.6 versus 36.8 weeks).

National guidelines have approved PIGF testing to rule out suspected pre-eclampsia in the UK.¹³ Hypothetical economic models have found that PIGF-based testing gives a cost-saving of between £330 and £1032^{13–15} per woman tested.^{16–23} These models have not examined trial data where use of PIGF has been incorporated into clinical care.

The PARROT trial provides an opportunity to assess the cost implications of implementing PIGF testing into the health service with clinical data, and the benefit of a controlled comparison group. The aim of this study was to conduct a within-trial analysis to calculate the incremental cost per maternal adverse event prevented associated with implementing PIGF testing in maternity services in the National Health Service (NHS) in England, compared with current standard care.

The use of PIGF testing alongside a clinical management algorithm may enable clinicians to target resources to those at greatest need (women testing with a PIGF <100 pg/ml). This could aid clinical decision making, enabling appropriate risk stratification of care. We anticipated that women with normal PIGF (>100 pg/ml) could be managed with less intensive surveillance, providing a cost-saving per woman tested.¹³

Methods

This economic evaluation is a within-trial analysis using data from the PARROT trial and is from an NHS cost perspective.

Trial processes

The PARROT study was a multicentre stepped-wedge cluster-randomised controlled trial of PIGF testing alongside a clinical management algorithm in the assessment of women with suspected pre-eclampsia. Eleven UK maternity units (size 3000–9000 deliveries per year) took part. Women aged 18 years or older were invited to participate in the trial if they presented to antenatal assessment services with suspected pre-eclampsia (for example to maternity triage or the acute obstetric assessment unit) with a live, singleton fetus between 20⁺⁰ weeks and 36 weeks⁺⁶ of gestation.

Women with a diagnosis of pre-eclampsia at the time of clinical presentation were excluded. The maternity units (clusters) were randomly allocated to the order in which the intervention (revealed PIGF alongside a clinical management algorithm) was introduced. At the beginning of the trial, all units followed 'usual care', and every 6 weeks, a randomly allocated cluster would begin adoption of revealed PIGF testing. By the end of the trial, all clusters were recruiting with revealed PIGF testing. The PARROT trial reported outcomes in over 99% of the participants enrolled. The trial was approved by the London South East Research Ethics Committee (ref. 15/LO/2058).

The comparator group and the intervention

Within 'usual care', an additional blood sample was collected at enrolment and was processed on an electronically masked Triage (Alere, San Diego, CA, USA; now Quidel Cardiovascular Inc., San Diego, CA, USA) instrument according to the manufacturer's instructions, so that the result was recorded but not revealed to the clinical team. Women were managed by an attending obstetrician following local hospital practice based on the NICE guidance on the Management of Hypertension in Pregnancy.²⁴

Under the intervention conditions (PIGF testing alongside a management algorithm) women provided a blood sample which was processed within 4 hours on an unmasked Triage instrument (Alere, now Quidel Cardiovascular Inc.) according to the manufacturer's instructions. A result was given to the attending obstetrician to inform clinical care. The trial was deliberately pragmatic to reflect how PIGF may be adopted within a healthcare service. No prescriptive care schedules were recommended following PIGF testing. The management algorithm provided simple guidance only, incorporating serum PIGF concentrations categorised as normal (>100 pg/ml), low (12–100 pg/ml) or very low (<12 pg/ml) into the national (NICE) guidance for the Management of Hypertension in Pregnancy (Figure S1). Women with a serum PIGF concentration of >100 pg/ml followed a care pathway involving outpatient management and routine surveillance unless clinical parameters such as severe hypertension indicated otherwise. Those with low PIGF concentrations were advised to 'increase surveillance' with a greater frequency of antenatal care visits and fetal ultrasound scanning. Those with very low PIGF were 'assessed as pre-eclampsia', which included consideration for admission, intensive monitoring, and fetal ultrasound scanning.

The primary outcome in the trial was the time, in days, from presentation with suspected pre-eclampsia to the woman receiving a documented diagnosis of pre-eclampsia in the clinical notes. Secondary outcomes included adverse maternal and perinatal outcomes. Participants were followed up from the point of recruitment to the primary

postnatal discharge of the woman and infant pair. All data were taken from clinical records including handheld notes, electronic maternity records, and neonatal records.

Resource use and costs

Resource use data was prespecified. Maternal resource use included maternity outpatient appointments, antenatal hospital admission, and hospital admission associated with delivery. This included both standard and intensive care admissions. Infant resource use included routine care, and admission to a neonatal unit (special care, high-dependency, and intensive care).²⁵ Information was collected on mode of delivery based on reference cost categories (spontaneous vaginal, assisted delivery, planned caesarean, and emergency caesarean).^{26,27} The cost of delivery has been reported separately as it is included in the NHS Reference Costs used to calculate the cost per bed day, and hence it would be double-counting to include this in the Monte Carlo simulation.

Unit costs were obtained from NHS Reference Costs 2016/2017²⁷ and are reported in Table S1. All costs are weighted, based on the sum of the unit costs for each relevant Healthcare Resource Group multiplied by activity. The sum of costs is then divided by the sum of the activity to give a weighted cost per patient based on the frequency of each Health Care Resource Group. All neonatal admissions were given the same cost per bed day, as a weighted cost per bed day derived from the relevant Health Care Resource Group multiplied by length of stay provides a closer estimate of total cost than using activity costs based on ward type.²⁷

The cost of the PIGF test was estimated at £70 per test 2017/2018 (all prices given in Pound Sterling [£] [Quidel, Cardiovascular Inc.]). We conducted sensitivity analyses varying the cost of the test between UK£50 and £200.

Effectiveness outcome

Core outcome sets and patient involvement were not relevant to this secondary economic analysis. Quality-adjusted life years (QALYs) are considered the gold standard effectiveness outcome in economic evaluations.²⁸ The use of QALYs in economic evaluations of interventions in maternity services presents a number of challenges.²⁹ Patient-reported outcomes were also not collected as part of this trial, so QALYs calculated using a preference-based measure of health-related quality of life was not possible. Instead, effectiveness has been calculated as the mean number of maternal adverse events avoided per 1000 women with the intervention compared with current practice. This was calculated based on the maternal adverse events reported in the PARROT Trial.¹¹

Statistical analysis

Cost-savings associated with PIGF testing for suspected pre-eclampsia may differ by PIGF sub-group (normal, low, and very low), as demonstrated in previous economic models.¹⁹ Cost-savings may also differ based on final diagnosis, e.g. pre-eclampsia; gestational hypertension/chronic hypertension/small for gestational age or none of the above.¹⁹ Each participant was allocated to one of the nine sub-groups based on serum PIGF concentration and final diagnosis. These were included as covariates in each analysis.

Healthcare resource use was analysed using generalised linear mixed models (GLMM). Each of the nine categories was analysed separately to determine the most appropriate form of general linear model based on the Akaike information criterion (AIC). For all models except one, the two-part negative binomial model was the most appropriate. This model accounts for the probability that a participant uses a service, using a count (Poisson) model for values greater than zero. For neonate intensive care and high dependency unit (ICU/HDU) admissions, the complex GLMM would not converge. As a result this was modelled using logistic regression, and linear regression was used for length of stay for admitted infants only.

To account for the stepped-wedge cluster-randomised nature of the trial, all models included fixed effect of linear time and a random effect for centre.³⁰ Mean adjusted resource use (with standard errors) were calculated for each of the nine groups, and by trial allocation. The mean cost of delivery and 95% confidence intervals by trial allocation were calculated using a GLMM with log link and family gamma. All statistical analyses were undertaken using STATA version 14.2 (StataCorp, College Station, TX, USA)

Probabilistic model

A simple costing analysis of the data does not allow for exploration of the complex inter-relationship between PIGF concentration, participant diagnosis, and resource use. Due to the skewed, over-dispersed nature of the resource use data, and the fact that these analyses were not the primary powered end point in the PARROT trial, it is unlikely that we would find statistically significant results, and any significant results would require circumspect interpretation.³¹ Instead we have used predicted adjusted means (and standard errors) and Monte Carlo simulation to calculate the probability that PIGF testing is cost-saving compared with current practice for maternal costs, infant costs; delivery costs, and all costs combined. Values used in the model and their distributions are reported in Tables S2–S8.

Total cost differences between trial arms were calculated as total costs and as weighted costs. Weighting accounted

for the proportion of participants in each of the nine subgroups in each arm of the trial.

The number of adverse events was calculated using a beta distribution with Monte Carlo simulation for 5000 iterations of the model. The probability that PIGF testing was cost-effective compared with current practice was calculated as willingness to pay per adverse event avoided, multiplied by the number of adverse events avoided, minus the total cost per 1000 women with suspected pre-eclampsia. The probability that PIGF testing is cost-effective includes the cost of the PIGF test.

The model was run 5000 times, which was used to generate the cost-effectiveness acceptability curve (the probability that PIGF testing is cost-effective for a range of values of willingness to pay for an adverse event avoided).

The model was developed and run in Microsoft EXCEL FOR OFFICE 365 (Redmond, WA, USA).

Results

In all, 1005 women were included in the analysis, 434 with usual care and 571 with clinical care with PIGF testing. Among all participants, 236 (23.5%) had a PIGF <12 pg/ml, 385 (38.3%) a PIGF 12–100 pg/ml, and 384 (38.2%) had a PIGF > 100 pg/ml. There was no contamination between trial arms (i.e. no duplication of National Health Service numbers in the trial database).

Participant demographics

Women had a mean age of 31.49 years (SD 5.98 years) and a mean gestational age of 32–33 weeks' gestation at trial entry. In all, 66% of the women were white, 14% were black, 12% were Asian (Indian, Pakistani, Sri Lankan or Bangladeshi), 2% were of mixed ethnicity, and 6% were from Chinese or other ethnic backgrounds. The median body mass index at booking was 28.4 kg/m² (IQR 24.2–34.1). There was a history of pre-eclampsia in a previous pregnancy in 39%. Full demographics and outcomes have been reported in the main trial paper.¹¹ The proportion of women in each diagnostic and PIGF subcategory in the trial are reported in Figure 1.

Costs

Descriptive statistics and average costs by diagnosis, PIGF test result, and trial arm allocation compared with current practice for appointments, length of stay or probability of admission are reported in Tables S2–S4. Cost differences (actual and weighted) and the proportion of times clinical care with PIGF testing costs less than current practice is reported in Tables 1 and 2. There was no difference in the cost of delivery between the two groups, with an average cost of delivery of £3,372 with PIGF testing, (95% CI

£3,258 to £3,484) and an average cost of £3,318 with usual care (95% CI £3,187 to £3,450).

Outpatient appointments had lower costs for all subgroups, with 100% of iterations of the model being cost-saving with PIGF testing. Maternal inpatient admission costs were greater with PIGF testing. This was mostly due to increased costs for women with a final pre-eclampsia diagnosis from appropriate management. Overall there was a reduction in costs for women admitted to intensive or high-dependency care (£86 weighted cost saving per woman, in 78.74% of iterations) and infant neonatal admissions, although with lower certainty (£71 weighted cost saving per infant in 50.4% of iterations).

Overall, the average weighted cost-saving per woman with PIGF testing was £147 in 66.6% of iterations. For women and infants combined, the average weighted cost-saving with PIGF testing was £149 per woman in 55.5% of iterations of the model, when accounting for a PIGF test cost of £70. Without accounting for the cost of PIGF testing, the average weighted cost saving per woman tested was £219 in 59.9% of iterations. Table 3 presents the probability that PIGF testing is cost-saving for a range of PIGF testing prices.

Cost-effectiveness

Clinical care with PIGF testing resulted in an average of 15 fewer maternal adverse events per 1000 women tested compared with usual care. PIGF testing dominated usual care in that it cost less and resulted in fewer maternal adverse events. There is a 72% probability that the intervention is cost-effective at a £20,000 willingness to pay for an adverse event prevented (see Figure S2).

Discussion

Main findings

The use of PIGF testing for suspected preterm pre-eclampsia has a 59.9% probability of representing a cost-saving compared with current practice, with a total cost-saving of £149 per woman when including the cost of the test (in this instance, Triage PIGF at £70 per test). Given that there were 646 794 births in England in 2017,³² 10% of pregnant women have suspected pre-eclampsia, and 30% of these present before 37 weeks' gestation, PIGF testing could be performed in approximately 38 800 pregnant women per year. This would result in a potential cost saving of £2,891,196 each year across the English NHS. The majority of cost-savings associated with PIGF testing are through a reduction seen in maternal outpatient appointments in women testing with a PIGF >100 pg/ml. Our resource use data suggest that where PIGF testing is implemented, high-risk women (for example those with low or very low PIGF) are more




Figure 1. Proportion of women in each diagnostic and PIGF category in the PARROT trial. CHT, chronic hypertension; GH, gestational hypertension; SGA, small for gestational age.

appropriately managed, as shown by the increased antenatal inpatient costs in these groups. With different commercial assay prices, the magnitude of the cost savings will depend on the cost per test. PIGF testing results in fewer maternal adverse events for a lower cost than usual care, i.e. PIGF testing dominates usual care, and hence no incremental cost per adverse event prevented is reported.

Strengths and limitations

The strengths of this study are in the direct comparison of resource use between women undergoing PIGF testing against women with usual care using trial data. The trial included NHS maternity units participating from across the UK, with prospective recruitment of an ethnically and socio-demographically varied group of participants, enabling generalisability to the broader NHS setting.

Our analysis evaluates the impact that clinical decisions have on resource use following PIGF testing as compared with usual care. We report the cost-savings and maternal adverse events averted. Usually a cost per adverse event reported should be avoided due to double-counting: adverse events are included in both the costs and the

effectiveness estimate. However, within our trial we did not include resource use assessment beyond the primary post-natal discharge of the mother and infant pair. We therefore did not capture any ongoing costs associated with maternal adverse events. In the PARROT trial there were five serious adverse events with usual care (two eclamptic fits, two strokes, and one cardiac arrest in four women) compared with no such corresponding events with PIGF testing. It was not possible to include community rehabilitation costs or resource use associated with ongoing medical management and readmissions. We were unable to assess health-related quality of life and wellbeing scores, and any impact on loss of earnings associated with these serious adverse events, which may be significant. Our estimated cost-saving is therefore likely to be a conservative estimate.

Interpretation

In this study, we have shown a modest cost-saving in comparison with other studies.^{16,17,19–23} Previous health economic studies of the implementation of PIGF testing in clinical care were based on hypothetical assumptions of reduction in resource use, with greater cost-savings than we have presented in this analysis. Current ‘usual care’

Table 1. Results of model and Monte Carlo Simulation: total cost difference per patient for PlGF minus current practice (actual, weighted, and percentage of 5000 iterations that are cost-saving) for maternal costs. All prices given in GBP (£)

Resource use	PIGF (pg/ml) Statistic	PIGF >100		PIGF 12-100		PIGF < 12		Total			
		Normal	GH/CHT/SGA	Pre-eclampsia	Normal	GH/CHT/SGA	Pre-eclampsia	Normal	GH/CHT/SGA	Pre-eclampsia	
Outpatient	Actual	-£647	-£479	-£335	-£608	-£139	-£590	-£638	-£282	-£345	-£4,062
	Weighted	-£82	-£93	-£21	-£28	-£20	-£113	-£3	-£10	-£67	-£436
Antenatal ward	Percentage <0	99.9%	98.4%	86.1%	98.2%	76.3%	100%	100%	84.3%	99.7%	100%
	Actual	£112	-£966	£1,422	-£174	£13	£777	-£770	£3,341	£582	£4,336
Labour ward	Weighted	£14	-£187	£88	-£8	£2	£148	-£4	£119	£113	£285
	Percentage <0	32.0%	99.3%	11.7%	67.2%	49.4%	18.8%	100%	0.6%	28.1%	17.3%
Maternal postnatal	Actual	£106	£107	£119	£275	£45	£13	-£166	-£54	-£58	£388
	Weighted	£13	£21	£7	£13	£7	£3	-£1	-£2	-£11	£49
Maternal ICU/HDU	Percentage <0	16.3%	18.8%	26.1%	4.9%	37.3%	46.8%	100%	62.8%	68.4%	17.4%
	Actual	-£116	-£464	£551	-£251	£3	£361	-£1,276	-£575	£418	-£1,350
Total Maternal	Weighted	-£15	-£90	£34	-£11	£0	£69	-£6	-£21	£81	£41
	Percentage <0	71%	98.6%	9.1%	74%	50.2%	9.8%	100%	80.6%	10.2%	36%
Total Maternal	Actual	£43	-£84	-£77	-£385	£52	-£336	-£0	£211	-£20	-£596
	Weighted	£5	-£16	-£5	-£18	£8	-£64	-£0	£8	-£4	-£86
Total Maternal	Percentage <0	20.2%	78.6%	59.5%	94.1%	20.9%	89.4%	0%	0%	51.2%	78.7%
	Actual	-£502	-£1,887	£1,679	-£1,142	-£26	£225	-£2,850	£2,641	£577	-£1,284
Total Maternal	Weighted	-£64	-£365	£103	-£52	-£4	£43	-£14	£94	£112	-£147
	Percentage <0	88.7%	100%	10.3%	95.1%	52.4%	40.9%	100%	5.4%	30.9%	66.6%

Actual values derived from adjusted models accounting for PlGF and final diagnosis. CHT, chronic hypertension; GH, gestational hypertension; SGA, small for gestational age; Weighted, weighted for proportion of women in each of the nine PlGF/Diagnostic groups—to calculate the weighted average cost per woman.

Table 2. Results of model and Monte Carlo simulation: total cost difference per patient for PIGF minus current practice (actual, weighted, and percentage of 5000 iterations that are cost-saving) for infant and total costs. All prices given in GBP (£)

Resource use	PIGF (pg/ml) Statistic	PIGF > 100		PIGF 12–100		PIGF < 12		GH/CHT/SGA	Pre-eclampsia	Total
		Normal	Pre-eclampsia	Normal	Pre-eclampsia	Normal	Pre-eclampsia			
Infant ICU/HDU	Actual	£187	£84	£86	£941	£0	£1,061	£7,079	£818	£6,932
	Weighted	£24	£5	£4	£138	£0	£202	£253	£158	£195
	Percentage <0	0%	23%	100%	95.6%	0%	0.6%	95.2%	16.5%	65%
Infant SCBU	Actual	£183	£393	£379	£376	£0	£558	£292	£610	£227
	Weighted	£23	£24	£17	£55	£0	£106	£10	£118	£122
	Percentage <0	98.1%	15.1%	88.6%	76.5%	0%	21.6%	53.1%	35.1%	37.7%
Total Infant	Actual	£4	£477	£465	£1,317	£0	£1,619	£7,371	£1,428	£6,705
	Weighted	£0	£29	£21	£194	£0	£309	£264	£276	£72
	Percentage <0	70.6%	13.8%	91.7%	94.9%	0%	2.9%	89.3%	22.7%	50.4%
Total maternal & infant costs	Actual	£498	£2157	£1607	£1343	£2850	£1845	£4730	£2005	£7990
	Weighted	£63	£133	£73	£197	£14	£352	£169	£388	£219
	Percentage <0	89.0%	13.2%	97.9%	88.2%	100%	8.0%	75.5%	18.6%	59.9%

Actual values derived from adjusted models accounting for PIGF and final diagnosis. CHT, chronic hypertension; GH, gestational hypertension; SGA, small for gestational age; Weighted, weighted for proportion of women in each of the nine PIGF/Diagnostic groups—to calculate the weighted average cost per woman.

Table 3. Probability that PIGF plus management algorithm is cost-saving for a range of costs per PIGF test. All prices given in GBP (£)

Cost per PIGF test	Probability cost-saving—Maternal costs only	Probability cost-saving—Infant costs only	Probability cost-saving—Maternal and Infant costs
£50	60.7%	46.6%	56.9%
£100	55.3%	42.2%	53.5%
£150	49.5%	38.2%	50.0%
£200	43.6%	34.4%	46.7%

relies upon imperfect stratification of pregnancies with suspected pre-eclampsia by obstetricians causing resource-intensive investigation of women. PIGF testing enables more appropriate stratification, targeting resource use to where it is more clinically appropriate. The conservative cost-saving presented in our analysis is due to a redistribution in maternity and neonatal resource use with PIGF testing, rather than an overall reduction in resource use that was anticipated by hypothetical models.

The PARROT trial evaluated PIGF testing in women presenting with suspected pre-eclampsia. The PARROT trial did not assess indications for or frequency of repeat PIGF testing. There is currently no mandate for repeated PIGF testing outside of research settings but it may impact further on maternal and perinatal outcomes, and subsequently on health resource use. The optimum frequency of repeated PIGF measurement remains uncertain but is likely that repeat sampling will impact on costs associated with the implementation of PIGF testing. This could be both in the cost of additional tests and in cost-savings associated with better stratification of care and avoidance of further morbidity.

Conclusion

Clinical care with PIGF testing is cost-saving, and is associated with reduced numbers of maternal adverse events compared with usual care. Given that PIGF testing has also been shown to be associated with an improvement in the time to diagnosis of pre-eclampsia,¹¹ this analysis supports a role for implementation of PIGF in antenatal services for the assessment of women with suspected pre-eclampsia.

Disclosure of interests

KED, LCC, PS, JEM, JCG, RB, GB, SB, JF, AK, and AS have no conflicts of interest. RMH has received consulting fees from Alere, outside the submitted work. Completed disclosure of interests forms are available to view online as Supporting Information.

Contribution to authorship

All authors were involved in the study conception and in securing funding for the study. Clinical study data analysis was undertaken by KED, LCC, and PS. Health economic analysis was undertaken by RMH. The manuscript was written by KED and RMH, with assistance from LCC, JCG, JEM, PS, GB, SB, RB, JF, AK, and AHS. All authors approved the final version of the manuscript.

Details of ethics approval

The trial was approved by the London South East Research Ethics Committee (ref. 15/LO/2058) on 21 January 2016.

Funding

This study was supported by grants from the National Institute for Health Research, Research for Patient Benefit Programme (PB-PG-0214-33054) and National Institute for Health Research Professorship (Chappell RP-2014-05-019). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Acknowledgements

We thank all women who participated in the PARROT Trial.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. PARROT Trial Clinical Management Algorithm.

Figure S2. Probability that PIGF testing in women presenting with pre-eclampsia compared with current practice is cost-effective for a range of values of willingness to pay for a maternal adverse event prevented.

Table S1. Unit costs (per day for inpatient stays) for resource use taken from 2016/2017 National Schedule of Reference Costs (2016/2017 GBP).

Table S2. Model inputs for revealed PIGF testing for antenatal costs.

Table S3. Model inputs for revealed PIGF testing for postnatal costs.

Table S4. Model inputs for revealed PIGF testing for infant costs.

Table S5. Model inputs in concealed PIGF testing for antenatal costs.

Table S6. Model inputs in concealed PIGF testing for postnatal costs.

Table S7. Model inputs in concealed PIGF testing for infant costs.

Table S8. Results of model: actual total cost per patient for PIGF and usual care. ■

References

- 1 Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. *Ultrasound Obstet Gynecol* 2018;51:743–50.
- 2 Say L, Chou D, Gemmill A, Tunçalp O, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. *Lancet Glob Health* 2014;2:e323–33.
- 3 Stevens W, Shih T, Incerti D, Ton TGN, Lee HC, Peneva D, et al. Short-term costs of preeclampsia to the United States health care system. *Am J Obstet Gynecol* 2017;217:237–48.e16.
- 4 Villar J, Repke J, Markush L, Calvert W, Rhoads G. The measuring of blood pressure during pregnancy. *Am J Obstet Gynecol* 1989;161:1019–24.
- 5 Durnwald C, Mercer B. A prospective comparison of total protein/creatinine ratio versus 24-hour urine protein in women with suspected preeclampsia. *Am J Obstet Gynecol* 2003;189:848–52.
- 6 Waugh J, Bell SC, Kilby MD, Lambert P, Shennan A, Halligan A. Urine protein estimation in hypertensive pregnancy: which thresholds and laboratory assay best predict clinical outcome? *Hypertens Pregnancy* 2005;24:291–302.
- 7 Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. *Lancet* 2010;376:631–44.
- 8 Meis PJ, Goldenberg RL, Mercer BM, Iams JD, Moawad AH, Miodovnik M, et al. The preterm prediction study: risk factors for indicated preterm births. Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. *Am J Obstet Gynecol* 1998;178:562–7.
- 9 Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest* 2003;111:649–58.
- 10 Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. *Circulation* 2013;128:2121–31.
- 11 Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. *Lancet* 2019;393:1807–18.
- 12 von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F, Cote AM, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. *Lancet* 2011;377:219–27.
- 13 NICE. PIGF-based testing to help diagnose suspected pre-eclampsia (Triage PIGF test, Elecsys immunoassay sFlt-1/PIGF ratio, DELFIA Xpress PIGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PIGF plus Kryptor PE ratio). 2016.
- 14 Curtis L, Burns, A. Unit Costs of Health and Social Care 2017. Canterbury: Personal Social Services Research Unit, University of Kent. 2017.
- 15 Purchasing Power Parity. [https://stats.oecd.org/Index.aspx?DataSetCode=SNA_TABLE4]. Accessed 13 December 2018.
- 16 Hadker N, Garg S, Costanzo C, Miller JD, Foster T, van der Helm W, et al. Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective. *J Med Econ* 2010;13:728–37.

- 17 Schnettler WT, Dukhovny D, Wenger J, Salahuddin S, Ralston SJ, Rana S. Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia. *BJOG* 2013;120:1224–32.
- 18 Zakiyah N, Postma MJ, Baker PN, van Asselt AD. Pre-eclampsia diagnosis and treatment options: a review of published economic assessments. *Pharmacoeconomics* 2015;33:1069–82.
- 19 Duckworth S, Chappell LC, Seed PT, Mackillop L, Shennan AH, Hunter R. Placental Growth Factor (PlGF) in women with suspected pre-eclampsia prior to 35 weeks' gestation: a budget impact analysis. *PLoS ONE* 2016;11:e0164276.
- 20 Frampton GK, Jones J, Rose M, Payne L. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis. *Health Technol Assess* 2016;20:1–160.
- 21 Figueira SF, Wolf C, D'Innocenzo M, de Carvalho JPV, Barbosa MG, Zlotnik E, et al. Economic evaluation of sFlt-1/PlGF ratio test in pre-eclampsia prediction and diagnosis in two Brazilian hospitals. *Pregnancy Hypertens* 2018;13:30–6.
- 22 Vatish M, Strunz-McKendry T, Hund M, Allegranza D, Wolf C, Smare C. sFlt-1/PlGF ratio test for pre-eclampsia: an economic assessment for the UK. *Ultrasound Obstet Gynecol* 2016;48:765–71.
- 23 Frusca T, Gervasi MT, Paolini D, Dionisi M, Ferre F, Cetin I. Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia. *J Matern Fetal Neonatal Med* 2017;30:2166–73.
- 24 National Institute for Clinical Excellence Clinical Guideline 107: Hypertension in Pregnancy, the Management of Hypertensive Disorders during Pregnancy. London: NICE. 2010.
- 25 British Association of Perinatal Medicine. *Categories of care 2011 [press release]*. London: British Association of Perinatal Medicine; 2011. p 2011.
- 26 NHS Reference Costs 2013-2014. In: Department of Health and Social Care. Gov.UK.
- 27 NHS Improvement, Reference Cost Collection. [<https://improvement.nhs.uk/resources/reference-costs/>]. Accessed 20 December 2018
- 28 NICE. Developing NICE Guidelines. Incorporating Economic Evaluation. London: NICE. 2018.
- 29 Ungar WJ. Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated? *Pharmacoeconomics* 2011; 29:641–52.
- 30 Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. *BMJ* 2015;350:h391.
- 31 Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. *Health Technol Assess* 1999;3:1–134.
- 32 Office for National Statistics. [<https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/bulletins/birthsummarytablesenglandandwales/2017>]. Accessed 20 December 2018.